Clinical Trial

Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma

Study acronym: MRD2START
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study was a multicenter, randomized, phase 3 trial to determine whether adjuvant chemotherapy including tisleliizumab improves recurrence-free survival compared to follow-up alone without chemotherapy in patients with curatively resected esophageal squamous cell carcinoma.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-31; most recent amendment 2026-05-29.
Trial Details
NCT Number NCT06914011
Lead Sponsor Asan Medical Center
Conditions Esophageal Cancer
Enrollment 172 participants
Start Date 2026-05-06
Primary Completion 2031-06-28 (estimated)
Study Completion 2034-05-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-02